The Expert Committee noted that infections of the eye and surrounding structures are frequent around the world and are an important cause of blindness. Given increasing concerns about overuse of antibiotics, the emergence of antimicrobial resistance and the need to guarantee prompt access to highly beneficial treatments, the Expert Committee noted the importance of revising and updating the Model Lists to provide clear information on the use of antibiotics in ocular infections. With regard to conjunctivitis, topical anti-infectives currently included on the Model Lists are gentamicin, ofloxacin and tetracycline (each with a square box). The Committee noted that based on the evidence and guidelines reviewed in the application topical antibiotics are indicated for moderate to severe infection and can be considered in mild cases. The available evidence does not make it possible to identify specific, preferred antibiotics for this indication. The Committee therefore endorsed the listings for gentamicin, ofloxacin and tetracycline for the treatment of conjunctivitis. Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, S01AE Fluoroquinolones, be specified as therapeutic alternatives under the square box listing for ofloxacin on the EML and EMLc.